These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 8551962)

  • 1. Meetings on vaccine studies towards the control of leishmaniasis. UNDP/World Bank/WHO Special Program for Research and Training in Tropical Diseases (TDR) February 13-22 and April 4-5, 1995.
    Grimaldi Júnior G
    Mem Inst Oswaldo Cruz; 1995; 90(4):553-6. PubMed ID: 8551962
    [No Abstract]   [Full Text] [Related]  

  • 2. Second-generation vaccines against leishmaniasis.
    Coler RN; Reed SG
    Trends Parasitol; 2005 May; 21(5):244-9. PubMed ID: 15837614
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Parasite candidate vaccines: a warning from polymorphic Leishmania populations.
    Guerbouj S; Guizani I; Victoir K; Le Ray D; Dujardin JC
    Parasitol Today; 2000 Jun; 16(6):265. PubMed ID: 10827439
    [No Abstract]   [Full Text] [Related]  

  • 4. Vaccines for leishmaniasis: from proteome to vaccine candidates.
    Schroeder J; Aebischer T
    Hum Vaccin; 2011; 7 Suppl():10-5. PubMed ID: 21245661
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identifying vaccine targets for anti-leishmanial vaccine development.
    Sundar S; Singh B
    Expert Rev Vaccines; 2014 Apr; 13(4):489-505. PubMed ID: 24606556
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vaccines against leishmaniasis.
    Modabber F
    Ann Trop Med Parasitol; 1995 Dec; 89 Suppl 1():83-8. PubMed ID: 8745930
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Present status of antileishmanial vaccines.
    Ghosh M; Bandyopadhyay S
    Mol Cell Biochem; 2003 Nov; 253(1-2):199-205. PubMed ID: 14619970
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The challenges on developing vaccine against visceral leishmaniasis.
    Jerônimo SM; Pearson RD
    Rev Soc Bras Med Trop; 2016; 49(4):395-7. PubMed ID: 27598623
    [No Abstract]   [Full Text] [Related]  

  • 9. Recombinant DNA-derived leishmania proteins: from the laboratory to the field.
    Kubar J; Fragaki K
    Lancet Infect Dis; 2005 Feb; 5(2):107-14. PubMed ID: 15680780
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunization with H1, HASPB1 and MML Leishmania proteins in a vaccine trial against experimental canine leishmaniasis.
    Moreno J; Nieto J; Masina S; Cañavate C; Cruz I; Chicharro C; Carrillo E; Napp S; Reymond C; Kaye PM; Smith DF; Fasel N; Alvar J
    Vaccine; 2007 Jul; 25(29):5290-300. PubMed ID: 17576026
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recent advances in vaccines for leishmaniasis.
    Requena JM; Iborra S; Carrión J; Alonso C; Soto M
    Expert Opin Biol Ther; 2004 Sep; 4(9):1505-17. PubMed ID: 15335317
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Leishmanial amastigote antigen P-2 induces major histocompatibility complex class II-dependent natural killer-cell reactivity in cells from healthy donors.
    Nylén S; Maasho K; McMahon-Pratt D; Akuffo H
    Scand J Immunol; 2004 Mar; 59(3):294-304. PubMed ID: 15030581
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differences in immune responses against Leishmania induced by infection and by immunization with killed parasite antigen: implications for vaccine discovery.
    Mendonça SC
    Parasit Vectors; 2016 Sep; 9(1):492. PubMed ID: 27600664
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Progress towards a Leishmania vaccine.
    Tabbara KS
    Saudi Med J; 2006 Jul; 27(7):942-50. PubMed ID: 16830009
    [TBL] [Abstract][Full Text] [Related]  

  • 15. DNA based vaccination with a cocktail of plasmids encoding immunodominant Leishmania (Leishmania) major antigens confers full protection in BALB/c mice.
    Ahmed SB; Touihri L; Chtourou Y; Dellagi K; Bahloul C
    Vaccine; 2009 Jan; 27(1):99-106. PubMed ID: 18951941
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recent updates and perspectives on approaches for the development of vaccines against visceral leishmaniasis.
    Duarte MC; Lage DP; Martins VT; Chávez-Fumagalli MA; Roatt BM; Menezes-Souza D; Goulart LR; Soto M; Tavares CA; Coelho EA
    Rev Soc Bras Med Trop; 2016; 49(4):398-407. PubMed ID: 27598624
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Field trial of a vaccine against new world cutaneous leishmaniasis in an at-risk child population: how long does protection last?
    Armijos RX; Weigel MM; Romero L; Garcia V; Salazar J
    J Infect Dis; 2003 Jun; 187(12):1959-61. PubMed ID: 12792873
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunoprophylaxis against Leishmania infections with a semi-purified antigen.
    Monjour L; Ogunkolade BW; Vouldoukis I; Roseto A; Berneman A; Frommel D
    Trans R Soc Trop Med Hyg; 1986; 80(6):1013. PubMed ID: 3603634
    [No Abstract]   [Full Text] [Related]  

  • 19. [Monoclonal antibodies against defined Leishmania antigens protect mice against infection by different species of Leishmania].
    Monjour L; Berneman A; Vouldoukis I; Domurado M; Guillemin MC; Chopin C; Alfred C; Roseto A
    C R Acad Sci III; 1985; 300(9):395-8. PubMed ID: 3922585
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Further trials of a vaccine against American cutaneous leishmaniasis.
    Mayrink W; Antunes CM; Da Costa CA; Melo MN; Dias M; Michalick MS; Magalhães PA; De Oliveira Lima A; Williams P
    Trans R Soc Trop Med Hyg; 1986; 80(6):1001. PubMed ID: 3299899
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.